Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Pregnancy and Childbirth

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 5 · 83.3%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Heparin prophylaxis vs no treatment/placebo

Adverse effects sufficient to stop treatment · pregnant women at increased risk of VTE during pregnancy and the early postnatal period

It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes adverse effects sufficient to stop treatment compared with no treatment/placebo (very low certainty).

1 finding from 1 review

Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period 2021 · Cochrane Headline outcomes only
RR 0.49 [0.05, 5.31]
1 study · 139 participants
Very low

LMWH prophylaxis vs UFH

Adverse effects sufficient to stop treatment · pregnant women at increased risk of VTE during pregnancy and the early postnatal period

It is very uncertain whether antenatal (± postnatal) prophylaxis: LMWH changes adverse effects sufficient to stop treatment compared with UFH (very low certainty).

1 finding from 1 review

Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period 2021 · Cochrane Headline outcomes only
RR 0.07 [0.01, 0.54]
2 studies · 226 participants
Very low

Heparin prophylaxis vs no treatment/placebo

Maternal death · pregnant women at increased risk of VTE during pregnancy and the early postnatal period

The review found no eligible studies for this question.

1 finding from 1 review

Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Heparin prophylaxis vs no treatment/placebo

Symptomatic thromboembolic events ( · pregnant women at increased risk of VTE during pregnancy and the early postnatal period

It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic thromboembolic events ( compared with no treatment/placebo (very low certainty).

1 finding from 1 review

Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period 2021 · Cochrane Headline outcomes only
RR 0.39 [0.08, 1.98]
4 studies · 476 participants
Very low

Heparin prophylaxis vs no treatment/placebo

Symptomatic PE · pregnant women at increased risk of VTE during pregnancy and the early postnatal period

It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic PE ( compared with no treatment/placebo (very low certainty).

1 finding from 1 review

Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period 2021 · Cochrane Headline outcomes only
RR 0.33 [0.02, 7.14]
3 studies · 187 participants
Very low

Heparin prophylaxis vs no treatment/placebo

Symptomatic DVT · pregnant women at increased risk of VTE during pregnancy and the early postnatal period

It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic DVT ( compared with no treatment/placebo (very low certainty).

1 finding from 1 review

Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period 2021 · Cochrane Headline outcomes only
RR 0.33 [0.04, 3.1]
4 studies · 227 participants
Very low